Autism risk tied to everyday medications in new study: acetaminophen not to blame

X Facebook WhatsApp

A new, large-scale analysis raises fresh questions about whether certain prescription drugs taken during pregnancy could be linked to a higher chance of an autism diagnosis in children. The finding matters now because millions of pregnancies involve at least one prescription medication, and clinicians and expectant parents need clearer evidence to weigh risks and benefits.

The study, published in Molecular Psychiatry, examined more than six million births in the United States and identified an association between prenatal exposure to a set of medicines that interfere with cholesterol synthesis and a higher likelihood of later autism spectrum disorder diagnoses. Researchers say the result points to a biological pathway worth deeper investigation—not a confirmed cause.

How the link was identified

Investigators compared medication records from pregnancy with later developmental outcomes, adjusting for common maternal conditions such as depression and cardiovascular disease. They report that exposure to at least one of the implicated drugs was associated with about a 47% relative increase in autism risk. When four or more of these medications were prescribed during pregnancy, the observed risk rose to more than double that baseline.

The team focused on drugs that interrupt a specific step in the body’s cholesterol production pathway. That disruption can lead to accumulation of intermediate molecules that prior laboratory work suggests may harm developing neural cells and interfere with how the fetal brain forms connections.

Which medicines were involved

Rather than common over-the-counter pain relievers, the medications flagged by the study spanned several prescription classes. Below is a grouped list of the agents the researchers identified:

Antidepressants: Sertraline (Zoloft), Fluoxetine (Prozac), Bupropion (Wellbutrin), Trazodone (Desyrel)

Anxiolytic: Buspirone (Buspar)

Antipsychotics: Aripiprazole (Abilify), Cariprazine (Vraylar), Haloperidol (Haldol)

Beta-blockers / Heart medications: Metoprolol (Lopressor), Propranolol (Inderal), Nebivolol (Bystolic)

Statins (cholesterol-lowering drugs): Atorvastatin (Lipitor), Simvastatin (Zocor), Rosuvastatin (Crestor), Pravastatin (Pravachol)

What this does—and doesn’t—prove

This is an observational study that identifies an association; it does not prove these drugs cause autism. Researchers attempted to account for known confounders, but unmeasured factors could still influence results. Biological plausibility exists because cholesterol plays a critical role in fetal brain development, yet translating that plausibility into clinical guidance requires more work.

Clinicians and patients should not interpret the findings as a directive to stop medications abruptly. The authors and independent experts emphasize that untreated maternal conditions—such as severe depression or cardiac disease—also carry risks for pregnancy and fetal health. Any medication adjustments must be made in partnership with a healthcare provider.

Implications and next steps

For doctors: the study suggests a need to review whether alternatives or closer monitoring are appropriate when multiple drugs that affect cholesterol metabolism are prescribed together during pregnancy.

For researchers: these results point to specific biochemical pathways to study in lab and animal models, and to the value of further epidemiological work that can control for more variables and examine timing, dose, and combinations of exposures.

For patients: if you are pregnant or planning pregnancy and take any of these medications, discuss risks and benefits with your clinician. In many cases, the safest option is a carefully supervised plan rather than an abrupt change.

At a time when prescription drug use in pregnancy is common, this study underscores why targeted research into how maternal treatments affect fetal development remains a public-health priority. The findings are a prompt for caution, further investigation, and careful clinical judgment—rather than a definitive verdict on any single medication.